WHY IT MATTERS: If Medicare begins covering cannabis-based medications, seniors who currently spend hundreds of dollars monthly out of pocket on cannabinoid therapies could see significant cost relief and improved access to physician-supervised treatment plans. CLINICAL OVERVIEW: The possibility of Medicare covering certain cannabis-based medications represents a significant shift in how the federal government treats cannabinoid therapeutics for older adults. From a clinical standpoint, this could dramatically improve access for seniors who currently pay entirely out of pocket for cannabis medicines, often on fixed incomes, while simultaneously catalyzing the rigorous research needed to establish evidence-based dosing protocols and safety profiles for this population.
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
WHY IT MATTERS: If you or a loved one is living with Alzheimer’s-related agitation, the expansion of this clinical trial means more opportunities to access investigational cannabinoid therapy and brings us closer to having FDA-reviewed evidence for cannabis-based treatment options in dementia care. CLINICAL OVERVIEW: The expansion of clinical trial sites for IGC Pharma’s Phase 2 CALMA trial investigating cannabinoid-based therapy for Alzheimer’s-associated agitation represents a meaningful step in building the evidence base for cannabis medicine in neurodegenerative disease. Alzheimer’s-related behavioral symptoms like agitation and aggression are notoriously difficult to manage with conventional medications, and cannabinoid therapies have shown early promise in addressing neuroinflammation and behavioral dysregulation through endocannabinoid system modulation.